tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of David Nierengarten, 510 are a BUY (85.43%), 79 are a HOLD (13.23%), 8 are a SELL (1.34%).
Analyst David Nierengarten, currently employed at WEDBUSH, carries an average stock price target met ratio of 43.1% that have a potential upside of 36.66% achieved within 184 days.
David Nierengarten’s has documented 1,238 price targets and ratings displayed on 85 stocks. The coverage is on Healthcare, Communication Services, Technology, Energy, Consumer Cyclical sectors.
Most recent stock forecast was given on BEAM, Beam Therapeutics.
Analyst best performing recommendations are on ABVX (ABIVAX SA).
The best stock recommendation documented was for ABVX (ABIVAX SA) at 6/2/2026. The price target of $90 was fulfilled within 1 day with a profit of $17.5 (24.14%) receiving and performance score of 241.38.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 07-Aug-2024
$60
$13.55 (29.17%)
1 months 10 days ago
(30-Sep-2026)
11/13 (84.62%)
$9.74 (19.38%)
385
Buy Since 10-Jun-2026
$95
$48.55 (104.52%)
$95
1 months 16 days ago
(24-Sep-2026)
0/3 (0%)
$43.3 (83.75%)
Buy Since 03-Oct-2024
$81
$34.55 (74.38%)
$85
1 months 17 days ago
(23-Sep-2026)
3/5 (60%)
$30.23 (59.54%)
135
Buy Since 17-Mar-2026
$76
$29.55 (63.62%)
$60
5 months 27 days ago
(13-May-2026)
3/4 (75%)
$13.31 (21.23%)
47
Buy Since 16-Feb-2024
$93
$46.55 (100.22%)
$63.33
6 months 5 days ago
(04-May-2026)
5/6 (83.33%)
$23.22 (33.28%)
427
Which stock is David Nierengarten most bullish on?
Which stock is David Nierengarten most reserved on?
What Year was the first public recommendation made by David Nierengarten?
